Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML
Status:
Terminated
Trial end date:
2019-07-10
Target enrollment:
Participant gender:
Summary
Assessment of safety and tolerability of drug combination and determine time on treatment,
Overall survival (OS) and response rate with patient disease burden, and type of disease